INFLUENCE OF SLCO1B1 GENE C.T521>C POLYMORPHISM ON THERAPY WITH SIMVASTATIN IN CORONARY HEART DISEASE PATIENTS

M.Yu. Kotlovskiy(1), A.A. Pokrovskiy(1, 2), A.V. Osedko(1), O.Ya. Osedko(1), O.S. Kotlovskaya(1), A.V. Yakimenko(1),
E.V. Kurdoyak(1), I.Yu. Yakimovich(3), N.V. Aksyutina(1), N.M. Titova(2), Yu.V. Kotlovskiy(1), A.M. Dygai(4)
1-Krasnoyarsk State Medical University, Partizana Zheleznyaka Str., 1, Krasnoyarsk, Russian Federation, 660022;
2-Siberian Federal University, Svobodniy av., 79, Krasnoyarsk, Russian Federation, 660041;
3-Siberian State Medical University, Moscovskiy tract, 2, Tomsk, Russian Federation, 634050;
4-E.D.Goldberg Research Institute of Pharmacology and Regenerative Medicine,
Lenin av., 3, Tomsk city, Russian Federation, 634028
E-mail: 13th_Apostol@mail.ru

Introduction. Carrier protein OATP1B1, encoded by the SLCO1B1gene, is involved in the transport of simvastatin into liver cells. SLCO1B1 gene polymorphisms influence on the functionality of the transporter, which could reflect on the efficacy and safety of treatment. Aim of the study. The study of the influence of SLCO1B1 Gene c.T521>C polymorphism on the efficacy of the treatment with simvastatin in coronary heart disease patients Materials and methods. The study group included 42 cases in whom there was assessed the level of total cholesterol, low-density lipoproteins and triglycerides before and after treatment. To identify a single nucleotide polymorphism MALDI-TOF mass spectrometer was used. Results. A statistically significant difference in the reducing of total cholesterol and achievement of cholesterol goal levels was revealed in dependence on the SLCO1B1 genotype. The efficiency of reduction of total cholesterol and the achievement of cholesterol goal levels in carriers of normal homozygote was higher than in C-alleles carriers by 61,9% and 34,8% correspondingly Conclusion. Thus, in our study there was found an association between polymorphic marker of the SLCO1B1 gene and the level of plasma lipids in the treatment of male coronary heart disease patients with simvastatin
Keywords: 
SLCO1B1, polymorphism, simvastatin